MIAMI, August 22, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. LGVN LGVNR (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the subscription period for its previously announced…Read More
Longeveron Rights Offering Subscription Period Begins Longeveron NASDAQLGVN Longeveron Inc Subscription Right NASDAQLGVNR
